title: Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells.
abstract: We have examined the chemotactic ability of tumor cell lines with different metastatic potential to plasma fibronectin in Transwell chamber assay. Human renal carcinoma cells with highly metastatic potential, SN12 C-2, chemotactically migrated to fibronectin (10 micrograms/ml) about three-fold more strongly than weakly metastatic SN12 C-4 cells. Similarly, murine melanoma B16-BL6 cells (highly metastatic) showed higher motility to soluble fibronectin in comparison with weakly metastatic B16-F1 cells. Anti-VLA-alpha 3 and beta 1 antibodies potently blocked the chemotaxis of both highly and weakly metastatic cells (SN12 C-2 and C-4) to fibronectin. This implies that the migration of both C-2 and C-4 cells to fibronectin is basically mediated by VLA-3 receptor. In contrast, the anti-VLA-alpha 5 antibody and RGDS peptide significantly inhibited the chemotaxis of SN12 C-2 cells to fibronectin, but did not affect weakly metastatic SN12 C-4 cells. These results suggest that the chemotactic ability to fibronectin positively correlates with the metastatic potential in SN12 and B16 cell lines, and that VLA-5 receptor is concerned in the motility of highly metastatic SN12 C-2 cells to soluble fibronectin.
authors: Institute of Immunological Science, Hokkaido University, Sapporo.
authors: J
authors: J
authors: Murata
authors: I
authors: I
authors: Saiki
authors: J
authors: J
authors: Yoneda
authors: I
authors: I
authors: Azuma
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000503:physiopathology*; D002465:Cell Movement / Q000187:drug effects; D002633:Chemotaxis / Q000187:drug effects*; D005353:Fibronectins / Q000276:immunology / Q000494:pharmacology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007680:Kidney Neoplasms / Q000473:pathology / Q000503:physiopathology*; D008546:Melanoma, Experimental / Q000473:pathology / Q000503:physiopathology*; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D017469:Receptors, Fibronectin / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D005353:Fibronectins; D036341:Intercellular Signaling Peptides and Proteins; D009842:Oligopeptides; D010455:Peptides; D017469:Receptors, Fibronectin; C076687:CS1 peptide; C046617:arginyl-glycyl-aspartyl-serine